Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria A Rodriguez

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
Clinical and Translational Radiation Oncology|May 23, 2022
Second malignancies in patients with Hodgkin's Lymphoma: Half a century of experienceBouthaina Shbib Dabaja, David Boyce-Fappiano, Wenli Dong, et al.
Cureus|February 5, 2024
Liquid Biopsies for Monitoring Medulloblastoma: Circulating Tumor DNA as a Biomarker for Disease Progression and Treatment ResponseBarbara Buccilli, Maria A Rodriguez Molina, Daniela P Redrovan Palomeque, et al.
Leukemia & Lymphoma|January 25, 2013
Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes databaseKarim E Abou-Nassar, Ann Vanderplas, Jonathan W Friedberg, et al.
British Journal of Haematology|January 20, 2007
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphomaNam H Dang, Barbara Pro, Fredrick B Hagemeister, et al.
Cancer|October 19, 2011
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national databaseAnita Kumar, Ann Vanderplas, Ann S LaCasce, et al.
British Journal of Haematology|July 22, 2014
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphomaJason R Westin, Peter McLaughlin, Jorge Romaguera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphomaJohn F Seymour, Barbara Pro, Lillian M Fuller, et al.
World Journal of Surgery|February 21, 2021
Humanitarian Surgical Missions in Times of COVID-19: Recommendations to Safely Return to a Sub-Saharan Africa Low-Resource SettingVíctor Lopez-Lopez, Ana Morales, Elisa García-Vazquez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2004
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphomaNam H Dang, Fredrick B Hagemeister, Barbara Pro, et al.
Cancer|January 28, 2003
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphomaJorge E Romaguera, L Jeffrey Medeiros, Frederick B Hagemeister, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Clinical and Translational Radiation Oncology|May 23, 2022
Second malignancies in patients with Hodgkin's Lymphoma: Half a century of experienceBouthaina Shbib Dabaja, David Boyce-Fappiano, Wenli Dong, et al.
Cureus|February 5, 2024
Liquid Biopsies for Monitoring Medulloblastoma: Circulating Tumor DNA as a Biomarker for Disease Progression and Treatment ResponseBarbara Buccilli, Maria A Rodriguez Molina, Daniela P Redrovan Palomeque, et al.
Leukemia & Lymphoma|January 25, 2013
Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes databaseKarim E Abou-Nassar, Ann Vanderplas, Jonathan W Friedberg, et al.
British Journal of Haematology|January 20, 2007
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphomaNam H Dang, Barbara Pro, Fredrick B Hagemeister, et al.
Cancer|October 19, 2011
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national databaseAnita Kumar, Ann Vanderplas, Ann S LaCasce, et al.
British Journal of Haematology|July 22, 2014
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphomaJason R Westin, Peter McLaughlin, Jorge Romaguera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphomaJohn F Seymour, Barbara Pro, Lillian M Fuller, et al.
World Journal of Surgery|February 21, 2021
Humanitarian Surgical Missions in Times of COVID-19: Recommendations to Safely Return to a Sub-Saharan Africa Low-Resource SettingVíctor Lopez-Lopez, Ana Morales, Elisa García-Vazquez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2004
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphomaNam H Dang, Fredrick B Hagemeister, Barbara Pro, et al.
Cancer|January 28, 2003
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphomaJorge E Romaguera, L Jeffrey Medeiros, Frederick B Hagemeister, et al.
Pageof 8